Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Canan John
  2. Issuer Name and Ticker or Trading Symbol
Merck & Co. Inc. [MRK]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Senior V-P, Controller
(Last)
(First)
(Middle)
ONE MERCK DRIVE
3. Date of Earliest Transaction (Month/Day/Year)
11/03/2009
(Street)

WHITEHOUSE STATION, NJ 08889-0100
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/03/2009   A   7,477.5705 A $ 0 (1) 0 D  
Common Stock - 401(k) Plan 11/03/2009   J   2,400.7973 A $ 0 (2) 0 I By 401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (3) 11/03/2009   A   3,750   03/02/2010(3) 03/02/2010(3) Common Stock 3,750 $ 0 0 D  
Restricted Stock Unit (3) 11/03/2009   A   4,950   02/28/2011(3) 02/28/2011(3) Common Stock 4,950 $ 0 0 D  
Restricted Stock Unit (3) 11/03/2009   A   5,775   04/24/2012(3) 04/24/2012(3) Common Stock 5,775 $ 0 0 D  
Restricted Stock Unit (3) 11/03/2009   A   9,681   07/24/2012(3) 07/24/2012(3) Common Stock 9,681 $ 0 0 D  
Stock Option (right to buy) $ 58.9105 11/03/2009   A   15,825   03/01/2003(4) 02/29/2012 Common Stock 15,825 $ 0 (4) 0 D  
Stock Option (right to buy) $ 49.9626 11/03/2009   A   18,990   02/28/2004(4) 02/27/2013 Common Stock 18,990 $ 0 (4) 0 D  
Stock Option (right to buy) $ 51.4697 11/03/2009   A   3,165   08/01/2004(4) 07/31/2013 Common Stock 3,165 $ 0 (4) 0 D  
Stock Option (right to buy) $ 62.0859 11/03/2009   A   12,660   02/22/2005(5) 02/21/2010 Common Stock 12,660 $ 0 (5) 0 D  
Stock Option (right to buy) $ 48.24 11/03/2009   A   10,000   02/27/2005(4) 02/26/2014 Common Stock 10,000 $ 0 (4) 0 D  
Stock Option (right to buy) $ 28.9 11/03/2009   A   10,000   11/01/2005(4) 10/31/2014 Common Stock 10,000 $ 0 (4) 0 D  
Stock Option (right to buy) $ 31.84 11/03/2009   A   10,000   02/25/2006(4) 02/24/2015 Common Stock 10,000 $ 0 (4) 0 D  
Stock Option (right to buy) $ 75.7638 11/03/2009   A   15,825   03/02/2006(5) 03/01/2011 Common Stock 15,825 $ 0 (5) 0 D  
Stock Option (right to buy) $ 34.47 11/03/2009   A   5,000   02/01/2007(4) 01/31/2016 Common Stock 5,000 $ 0 (4) 0 D  
Stock Option (right to buy) $ 35.09 11/03/2009   A   21,000   03/03/2007(4) 03/02/2016 Common Stock 21,000 $ 0 (4) 0 D  
Stock Option (right to buy) $ 44.19 11/03/2009   A   20,000   03/02/2008(4) 03/01/2017 Common Stock 20,000 $ 0 (4) 0 D  
Stock Option (right to buy) $ 44.3 11/03/2009   A   26,400   02/28/2009(4) 02/28/2018 Common Stock 26,400 $ 0 (4) 0 D  
Stock Option (right to buy) $ 23.45 11/03/2009   A   30,800   04/24/2010(4) 04/23/2019 Common Stock 30,800 $ 0 (4) 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Canan John
ONE MERCK DRIVE
WHITEHOUSE STATION, NJ 08889-0100
      Senior V-P, Controller  

Signatures

 Debra A. Bollwage as Attorney-in-Fact for John Canan   11/05/2009
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions").
(2) Received as part of the Transactions in exchange for an equivalent number of shares of MSD common stock held under the MSD 401(k) plan.
(3) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule.
(4) This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.
(5) This option vests on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.